Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.


The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page


My NCBI Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
2008 3
2009 4
2010 2
2011 2
2012 1
2013 4
2014 4
2015 4
2016 5
2017 1
2018 1
2019 6
2020 6
2021 3
2022 2
2023 0

Text availability

Article attribute

Article type

Publication date

Search Results

42 results

Results by year

Filters applied: . Clear all
Page 1
Toward Precision Phenotyping of Multiple Sclerosis.
Pitt D, Lo CH, Gauthier SA, Hickman RA, Longbrake E, Airas LM, Mao-Draayer Y, Riley C, De Jager PL, Wesley S, Boster A, Topalli I, Bagnato F, Mansoor M, Stuve O, Kister I, Pelletier D, Stathopoulos P, Dutta R, Lincoln MR. Pitt D, et al. Among authors: boster a. Neurol Neuroimmunol Neuroinflamm. 2022 Aug 30;9(6):e200025. doi: 10.1212/NXI.0000000000200025. Print 2022 Nov. Neurol Neuroimmunol Neuroinflamm. 2022. PMID: 36041861 Free PMC article. Review.
Best Practices for Intrathecal Baclofen Therapy: Troubleshooting.
Saulino M, Anderson DJ, Doble J, Farid R, Gul F, Konrad P, Boster AL. Saulino M, et al. Among authors: boster al. Neuromodulation. 2016 Aug;19(6):632-41. doi: 10.1111/ner.12467. Epub 2016 Jul 19. Neuromodulation. 2016. PMID: 27434299 Review.
Autoimmunity and long-term safety and efficacy of alemtuzumab for multiple sclerosis: Benefit/risk following review of trial and post-marketing data.
Coles AJ, Jones JL, Vermersch P, Traboulsee A, Bass AD, Boster A, Chan A, Comi G, Fernández Ó, Giovannoni G, Kubala Havrdova E, LaGanke C, Montalban X, Oreja-Guevara C, Piehl F, Wiendl H, Ziemssen T. Coles AJ, et al. Among authors: boster a. Mult Scler. 2022 Apr;28(5):842-846. doi: 10.1177/13524585211061335. Epub 2021 Dec 9. Mult Scler. 2022. PMID: 34882037 Free PMC article. Review.
Intracerebral haemorrhage during alemtuzumab administration.
Azevedo CJ, Kutz C, Dix A, Boster A, Sanossian N, Kaplan J. Azevedo CJ, et al. Among authors: boster a. Lancet Neurol. 2019 Apr;18(4):329-331. doi: 10.1016/S1474-4422(19)30076-6. Epub 2019 Feb 15. Lancet Neurol. 2019. PMID: 30777657 No abstract available.
Best Practices for Intrathecal Baclofen Therapy: Screening Test.
Boster AL, Bennett SE, Bilsky GS, Gudesblatt M, Koelbel SF, McManus M, Saulino M. Boster AL, et al. Neuromodulation. 2016 Aug;19(6):616-22. doi: 10.1111/ner.12437. Epub 2016 Jul 19. Neuromodulation. 2016. PMID: 27434115 Review.
Best Practices for Long-Term Monitoring and Follow-Up of Alemtuzumab-Treated MS Patients in Real-World Clinical Settings.
Barclay K, Carruthers R, Traboulsee A, Bass AD, LaGanke C, Bertolotto A, Boster A, Celius EG, de Seze J, Cruz DD, Habek M, Lee JM, Limmroth V, Meuth SG, Oreja-Guevara C, Pagnotta P, Vos C, Ziemssen T, Baker DP, Wijmeersch BV. Barclay K, et al. Among authors: boster a. Front Neurol. 2019 Mar 22;10:253. doi: 10.3389/fneur.2019.00253. eCollection 2019. Front Neurol. 2019. PMID: 30967831 Free PMC article. Review.
42 results